Maravai LifeSciences (MRVI) Expected to Announce Earnings on Monday

Maravai LifeSciences (NASDAQ:MRVI) is projected to release its Q2 2025 earnings data after the market closes on Monday, August 11th. Analysts expect the company to announce earnings of ($0.06) per share and revenue of $47.46 million for the quarter. Maravai LifeSciences has set its FY 2025 guidance at EPS.

Maravai LifeSciences (NASDAQ:MRVI) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). Maravai LifeSciences had a negative return on equity of 12.91% and a negative net margin of 67.14%. The business had revenue of $46.85 million during the quarter, compared to analysts’ expectations of $44.01 million. The firm’s revenue was down 26.9% compared to the same quarter last year. On average, analysts expect Maravai LifeSciences to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Maravai LifeSciences Stock Up 8.4%

NASDAQ:MRVI opened at $2.20 on Friday. The firm has a market cap of $560.25 million, a PE ratio of -1.93 and a beta of 0.28. The company has a debt-to-equity ratio of 0.60, a current ratio of 5.96 and a quick ratio of 5.17. The company has a 50-day moving average of $2.39 and a 200 day moving average of $2.70. Maravai LifeSciences has a 1-year low of $1.66 and a 1-year high of $9.95.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Craig Hallum reduced their target price on shares of Maravai LifeSciences from $12.00 to $10.00 and set a “buy” rating for the company in a report on Tuesday, May 13th. Robert W. Baird reduced their price target on shares of Maravai LifeSciences from $3.00 to $2.00 and set a “neutral” rating for the company in a research report on Tuesday, May 13th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $6.64.

Institutional Investors Weigh In On Maravai LifeSciences

A hedge fund recently raised its stake in Maravai LifeSciences stock. Jane Street Group LLC increased its holdings in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 1,463.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 380,403 shares of the company’s stock after buying an additional 356,067 shares during the period. Jane Street Group LLC owned about 0.15% of Maravai LifeSciences worth $841,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 50.25% of the company’s stock.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.